SCHEDULE 13G/A: BlackRock Discloses 7.6% Stake in Altimmune, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Altimmune, Inc.'s common stock.

Summary

• BlackRock, Inc. beneficially owns 6,133,427 shares of Altimmune, Inc. common stock.
• This ownership represents 7.6% of the total outstanding common stock of Altimmune, Inc.
• BlackRock holds sole voting power over 6,046,097 shares and sole dispositive power over 6,133,427 shares.
• No shared voting or dispositive power is reported by BlackRock, Inc.
• The filing reflects the securities beneficially owned by certain business units of BlackRock, Inc. and its subsidiaries and affiliates.
• BlackRock Investment Management, LLC is specifically identified as an entity beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of an ownership stake without explicit positive or negative commentary on the issuer's performance or prospects.

Positives

• BlackRock, Inc., a prominent institutional investor, holds a significant 7.6% stake in Altimmune, Inc., which may signal institutional confidence or interest in the company.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Altimmune, Inc.

Future Outlook

No forward-looking statements or guidance regarding Altimmune, Inc.'s future performance or strategic direction are provided in this ownership disclosure.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing is a standard institutional investment disclosure, reflecting BlackRock's passive ownership position in Altimmune, Inc., a company likely operating within the biotechnology or pharmaceutical sector. It does not offer broader industry trend analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock could be viewed positively, potentially signaling institutional confidence in Altimmune, Inc.

Key Dates

Keywords

Altimmune Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Management